Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XPA | P23025 | 9/20 | 0.79 |
| ▸ | CLEC4M | Q9H2X3 | 2/20 | 0.60 |
| ▸ | ERO1A | Q96HE7 | 2/20 | 0.58 |
| ▸ | KDM1A | O60341 | 1/20 | 0.58 |
| ▸ | MAOA | P21397 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 1/20 | 0.58 |
| ▸ | CTSB | P07858 | 1/20 | 0.56 |
| ▸ | EP300 | Q09472 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | GSK3A | P49840 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5457416 | 1.00 | XPA (0.79) | XPACLEC4MERO1AKDM1AMAOA | |
| SCHEMBL5462301 | 0.91 | XPA (0.81) | XPACLEC4MERO1AKDM1AMAOA | |
| SCHEMBL5462298 | 0.91 | XPA (0.81) | XPACLEC4MERO1AKDM1AMAOA | |
| SCHEMBL19654116 | 0.89 | XPA (1.00) | XPACLEC4MERO1AKDM1AMAOA | |
| SCHEMBL20840345 | 0.80 | XPA (0.73) | XPAERO1AKDM1AMAOAMAOB | |
| SCHEMBL20840344 | 0.80 | XPA (0.73) | XPAERO1AKDM1AMAOAMAOB | |
| SCHEMBL22219633 | 0.80 | XPA (0.73) | XPAERO1AKDM1AMAOAMAOB | |
| SCHEMBL20840310 | 0.79 | ERO1A (0.77) | XPAERO1AKDM1AMAOAMAOB | |
| SCHEMBL20848009 | 0.79 | ERO1A (0.77) | XPAERO1AKDM1AMAOAMAOB | |
| SCHEMBL20840309 | 0.79 | ERO1A (0.77) | XPAERO1AKDM1AMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070276011-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2007-11-29 | — | — | US | disclosed |
| EP-1666469-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | Institute of Medicinal Molecular Design, Inc. (JP) | 2006-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276011-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | SERPINE1, SERPINC1, SERPINB1 | XPA 2030/4885CLEC4M 2779/4885ERO1A 1559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.